Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Li, Lun ^a   Tian, Jin Hui ^a   Yang, Kehu ^a   Zhang, Peng ^b   Jia, Wen Qin ^a  

^a LANZHOU UNIVERSITY   (China)

^b Central Hospital of Nanyang City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRO 140; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; PRO-140 MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LYMPHADENOPATHY; MORTALITY; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD; ADULT; BLOOD; DRUG ADMINISTRATION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; META ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CCR5 RECEPTOR ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL;

EID: 84922392690     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008439.pub3     Document Type: Review

References (30)

1. ISRCTN45537485. Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double-blind, randomized, dose-cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV-1 infection]. Current Controlled Trials (http://controlled-trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014.
2. Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. Journal of Infectious Diseases 2008;198(9):1345-52. [PUBMED: 18771406]
3. Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases 2010;201(10):1481-7. [PUBMED: 20377413]
4. NCT00642707. Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&rank=1) accessed 23 July 2014.
5. Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrobrial Agents and Chemotherapy 2010;54(10):4137-42. [PUBMED: 20660677]
6. NCT00613379. A phase 2a, randomized, double-blind, placebo-controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&rank=1) accessed 23 July 2014.
7. Boesecke C, Pett SL. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Current Opinion in HIV and AIDS 2012;7(5):456-62.
8. Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. Journal of Virology 2003;77(4):2762-7.
9. Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007;364(2):281-290.
10. Khatib N, Das S. PRO 140-a novel CCR5 co-receptor inhibitor. Recent Patents on Anti-infective Drug Discovery 2010;5(1):18-22.
11. Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. Journal of Womens Health 2003;12(7):655-66.
12. Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 2006;50(10):3289-96.
13. Pugach P, Ketas TJ, Michael E, Moore JP. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008;377(2):401-7.
14. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of Virology 2005;79(13):8454-69.
15. Shearer WT, DeVille JG, Samson PM, Moye JH Jr, Fletcher CV, Church JA, et al. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). Journal of Allergy and Clinical Immunology 2006;118(2):518-21.
16. Tenorio AR. The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy. Current HIV/AIDS Reports 2011;8(1):1-3.
17. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology 2001;75(2):579-88.
18. NCT01272258. A trial of observed long-acting, anti-HIV treatment with a monoclonal CCR5 antibody (PRO 140) as an adjunct to a new, optimized, oral antiretroviral regimen in HIV-infected injection drug users with viral rebound and documented poor adherence. clinicaltrials.gov/show (http://www.clinicaltrials.gov/ct2/show/NCT01272258?term=NCT01272258&rank=1) accessed 23 July 2014.
19. AIDS info. PRO 140. http://www.aidsinfo.nih.gov/accessed 23 July 2014.
20. Biswas P, Tambussi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opinion on Pharmacotherapy 2007;8(7):923-33.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Louie M, Hogan C, Hurley A, Captan B, Flaherty J, Lamy P, et al. Determining the relative efficacy of Tenofovir DF using frequent measurements of HIV-1 RNA during a short course of monotherapy in antiretroviral drug naive individuals. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002.
23. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. EuroSIDA Study Group. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352(9142):1725-30.
24. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998;338(13):853-60.
25. Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. Journal of Acquired Immune Deficiency Syndromes 2004;37(5):1566-9.
26. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
27. Richard WK. Progenics Pharmaceuticals' HIV drug, PRO 140, receives FDA fast-track designation. www.natap.org/2006/HIV/022406_02.htm (accessed 18 June 2009).
28. Sivadasan A, Abraham OC, Rupali P, Pulimood SA, Rajan J, Rajkumar S, et al. High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. Journal of the Association of Physicians of India 2009;57:384-8.
29. UNAIDS 2009. 09 AIDS epidemic update. www.search.unaids.org/search.asp?lg=en&search=09%20AIDS%20epidemic%20update (accessed 18 November 2009).
30. UNAIDS 2013. UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf accessed 23 July 2014.